BAKER BROS. ADVISORS LP bought 196,608 shares of Kodiak Sciences Inc. at $89.86 for $17.7M on Sep 28, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Director
DIR
Filed Sep 30, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$17,666,310.14Shares × reported price
Shares traded
196,608Common Stock
Price per share
$89.86Reported price. Read footnotes for ranges.
% of reported position traded
0.98%This security and ownership context
Holdings after
20,159,386Indirect · See Footnotes
Trade date
Sep 28, 2026Buy
Filed
Sep 30, 2026, 4:31 PM ET2-day reporting delay
Accession
0001193125-26-409127Code P · Transaction 231862
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 19,962,778 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 28, 2026Buy186$86.72$16,130.24Trade 231847
Sep 28, 2026Buy3,114$86.72$270,051.37Trade 231848
Sep 28, 2026Buy957$86.81$83,081.19Trade 231849
Sep 28, 2026Buy16,036$86.81$1,392,152.51Trade 231850
Sep 28, 2026Buy3,790$86.94$329,510.56Trade 231851
Sep 28, 2026Buy63,539$86.94$5,524,214.09Trade 231852
Sep 28, 2026Buy4,485$87.51$392,466.65Trade 231853
Sep 28, 2026Buy75,176$87.51$6,578,388.64Trade 231854
Sep 28, 2026Buy5,880$88.57$520,774.55Trade 231855
Sep 28, 2026Buy98,561$88.57$8,729,261.94Trade 231856
Sep 28, 2026Buy6,428$88.65$569,816.49Trade 231857
Sep 28, 2026Buy107,772$88.65$9,553,556.71Trade 231858
Sep 28, 2026Buy4,932$89.60$441,924.96Trade 231859
Sep 28, 2026Buy82,673$89.60$7,407,798.42Trade 231860
Sep 28, 2026Buy11,729$89.86$1,053,915.16Trade 231861
Sep 29, 2026Buy619$84.24$52,145.86Trade 231863
Sep 29, 2026Buy10,381$84.24$874,517.24Trade 231864
Sep 29, 2026Buy1,195$85.40$102,056.59Trade 231865
Sep 29, 2026Buy20,031$85.40$1,710,707.49Trade 231866
Sep 29, 2026Buy84$85.89$7,214.38Trade 231867
Sep 29, 2026Buy1,416$85.89$121,613.87Trade 231868
22 transaction rows in this filing. Joint filers share the same rows.

KOD price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KOD · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −60%1w ago −66%1d ago −66%
Returns since7d −3.9%30d +4.6%90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $86.70 to $86.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F2: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F3: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. F4: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. F6: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F7: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.465, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F8: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $87.03 to $88.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F9: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.25 to $88.97, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F10: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.01 to $89.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F11: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.32 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F12: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.11 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F13: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.81 to $84.65, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F14: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.16 to $85.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F15: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.82 to $85.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.